Back

Human-porcine transcriptomics reveals resuscitation-responsive pathways in trauma shock

Gisby, J. S.; Purcell, R.; Withnell, I.; Cabrera, C. P.; Watson, D. S.; Masarone, S.; Hernandez Mir, G.; Savage, E.; Bourne, E.; Wozniak, E.; Mein, C. A.; Ross, J.; Pott, J.; Shepherd, J.; Pennington, D. J.; Watts, S.; Kirkman, E.; Brohi, K.; Barnes, M. R.

2026-02-03 intensive care and critical care medicine
10.64898/2026.01.31.26345216 medRxiv
Show abstract

Haemorrhage is the leading preventable cause of trauma death, primarily through ischaemic consequences that current treatments cannot adequately address. We combined human transcriptomic data (n=458) with a controlled porcine model of haemorrhagic shock to identify treatment-responsive molecular mechanisms. Using latent factorisation, we prioritised distinct molecular signatures of the human shock response, including stress signalling, neutrophil activation, and cytotoxic lymphocyte programmes. We assessed the behaviour of these pathways in the experimental porcine system, revealing that shock-initiated immune trajectories are not immutable: blood resuscitation normalised maladaptive transcriptomic changes whilst noradrenaline exacerbated them. While resuscitation modulated neutrophil, heat-shock, and barrier defence programmes, interferon and coagulation pathways were neither mortality-predictive nor treatment-responsive. A factor representing p38-MAPK/AP-1 stress signalling emerged as the dominant mortality-predictive pathway. An in silico small molecule screen identified p38 inhibitors as leading candidates for reversing shock-induced transcriptomic signatures. Our framework identifies modifiable pathways in trauma shock, prioritising p38-MAPK inhibition for therapeutic development and providing a systematic approach for trauma drug repurposing. One sentence summary: Human-porcine cross-analysis reveals treatment-modifiable molecular signatures of trauma shock, identifying potential therapeutic strategies.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
eLife
5422 papers in training set
Top 2%
17.3%
2
Science Translational Medicine
111 papers in training set
Top 0.1%
12.3%
3
Nature
575 papers in training set
Top 3%
10.0%
4
Nature Communications
4913 papers in training set
Top 36%
4.1%
5
eBioMedicine
130 papers in training set
Top 0.2%
3.9%
6
Scientific Reports
3102 papers in training set
Top 38%
3.5%
50% of probability mass above
7
Nature Medicine
117 papers in training set
Top 0.9%
3.5%
8
Cell Reports Medicine
140 papers in training set
Top 2%
3.0%
9
iScience
1063 papers in training set
Top 7%
3.0%
10
BMC Medicine
163 papers in training set
Top 2%
2.3%
11
JCI Insight
241 papers in training set
Top 3%
2.1%
12
Cell
370 papers in training set
Top 11%
1.8%
13
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.7%
14
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 34%
1.6%
15
Cell Reports
1338 papers in training set
Top 27%
1.3%
16
Blood Advances
54 papers in training set
Top 0.9%
1.3%
17
Science
429 papers in training set
Top 16%
1.3%
18
Science Advances
1098 papers in training set
Top 23%
1.2%
19
The EMBO Journal
267 papers in training set
Top 3%
1.2%
20
Nature Genetics
240 papers in training set
Top 6%
1.1%
21
British Journal of Anaesthesia
14 papers in training set
Top 0.6%
0.9%
22
Developmental Cell
168 papers in training set
Top 11%
0.9%
23
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
24
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.7%
0.7%
25
Nature Human Behaviour
85 papers in training set
Top 5%
0.7%
26
Immunity
58 papers in training set
Top 4%
0.7%
27
Journal of Clinical Investigation
164 papers in training set
Top 8%
0.6%
28
Neuron
282 papers in training set
Top 9%
0.6%
29
Heliyon
146 papers in training set
Top 8%
0.6%